Related Experiment Video
Updated: Jun 3, 2026
A Three-dimensional Model of Spheroids to Study Colon Cancer Stem Cells
Published on: January 22, 2021
Down-regulation of the global regulator SATB1 by statins in COLO205 colon cancer cells
C N Lakshminarayana Reddy1, V N Vyjayanti, Dimple Notani
1Discovery Research Division, Institute of Life Sciences, University of Hyderabad Campus, Hyderabad, India.
Abstract:
Special AT-rich sequence binding protein 1 (SATB1) regulates the expression of more than 1,000 genes in tumor cells. SATB1 expression has been implicated in metastasis, and its silencing results in reduced cancer progression and the reversion of metastatic cells to normal appearance. Therefore, any compound causing down-regulation of SATB1 expression or activity may be exploited for its therapeutic potential in terms of cancer regression. Earlier studies showed that the 3-hydroxy-3-methylglutaryl coenzymeA (HMG-CoA) reductase inhibitors (statin drugs), which are widely used to treat hypercholesterolemia, possess other pleotropic activities. These are now increasingly gaining attention for their cancer prevention abilities. However, the downstream interplay of the molecular mechanisms of such anti-cancer activities is unclear. Here, we show that SATB1 is down-regulated by statins in a time- and dose-dependent manner in COLO205 cells. This effect was statin-specific as the down-regulation of SATB1 was brought about by hydrophobic statins, such as simvastatin and fluvastatin, but not by hydrophilic pravastatin. Notably, treatment with mevalonate, an intermediate in the cholesterol and isoprenoid biosynthetic pathways, led to the inhibition of SATB1 down-regulation and cytotoxicity mediated by statins. Treatment with the proteasome inhibitors lactacystine and MG-132 inhibited the statin-mediated down-regulation of SATB1, suggesting that regulation occurs at the post-translational level. Thus, our results demonstrate a novel molecular mechanism for the anti-cancer activity of statin drugs in colon cancer cells, without invoking significant cytotoxicity.
Insights
Statins, used for high cholesterol, reduce cancer progression by down-regulating Special AT-rich sequence binding protein 1 (SATB1). This novel mechanism in colon cancer cells offers therapeutic potential without significant toxicity.
Area of Science:
- Molecular Biology
- Oncology
- Pharmacology
Background:
- Special AT-rich sequence binding protein 1 (SATB1) is a key regulator of over 1,000 genes in tumor cells, influencing metastasis and cancer progression.
- Statin drugs, primarily used for hypercholesterolemia, exhibit pleiotropic effects, including potential cancer prevention, but their molecular mechanisms remain unclear.
- Understanding how statins affect SATB1 could reveal new therapeutic strategies for cancer regression.
Purpose of the Study:
- To investigate the effect of statins on SATB1 expression in colon cancer cells.
- To elucidate the molecular mechanism underlying statin-mediated SATB1 down-regulation.
- To explore the therapeutic potential of statins in colon cancer based on SATB1 modulation.
Main Methods:
- COLO205 colon cancer cells were treated with various statins (simvastatin, fluvastatin, pravastatin) and mevalonate.
- Time- and dose-dependent effects of statins on SATB1 expression were analyzed.
- Proteasome inhibitors (lactacystine, MG-132) were used to investigate the post-translational regulation of SATB1.
Main Results:
- Statins, particularly hydrophobic ones like simvastatin and fluvastatin, significantly down-regulated SATB1 expression in a time- and dose-dependent manner.
- This SATB1 down-regulation was blocked by mevalonate, indicating a link to the cholesterol biosynthesis pathway.
- Proteasome inhibitors prevented statin-mediated SATB1 reduction, suggesting post-translational regulation.
Conclusions:
- Statins exert anti-cancer effects in colon cancer cells through the novel mechanism of down-regulating SATB1.
- The regulation of SATB1 by statins occurs at the post-translational level and is linked to the mevalonate pathway.
- This study identifies a promising therapeutic avenue for colon cancer utilizing statins to target SATB1, potentially without significant cytotoxicity.
Related Concept Videos
01:12Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
01:15Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
01:20The JAK-STAT Signaling Pathway